PE20211313A1 - Piperidinil-3-(ariloxi)propanamidas y propanoatos - Google Patents

Piperidinil-3-(ariloxi)propanamidas y propanoatos

Info

Publication number
PE20211313A1
PE20211313A1 PE2020001318A PE2020001318A PE20211313A1 PE 20211313 A1 PE20211313 A1 PE 20211313A1 PE 2020001318 A PE2020001318 A PE 2020001318A PE 2020001318 A PE2020001318 A PE 2020001318A PE 20211313 A1 PE20211313 A1 PE 20211313A1
Authority
PE
Peru
Prior art keywords
halo
substituted
optional substituents
alkyl
independently selected
Prior art date
Application number
PE2020001318A
Other languages
English (en)
Inventor
Zacharia Cheruvallath
Ben Johnson
Kristin Schleicher
Huikai Sun
Jason Green
Mingnam Tang
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PE20211313A1 publication Critical patent/PE20211313A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Referido a un compuesto de formula 1, o una sal farmaceuticamente aceptable este donde: X1 se selecciona de N y CR1; X2 se selecciona de N y CR2; X3 se selecciona de N y CR3; y X4 se selecciona de N y CR4; X13 es NR13 y X14 es CR15R16 o X13 es CH2 y X14 es NR14; L es NR8 y O; r se selecciona de 0 y 1; s se selecciona de 0 y 1; R5 se selecciona de (a) hidrogeno, halo, hidroxi y ciano; y (b) alquilo C1-4, cicloalquilo C3-6 y alcoxi C1-4, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo, oxo y fenilo que esta sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; cada R6 y R7 se selecciona independientemente halo y alquilo C1-3, o R6 y R7, junto con el atomo de carbono al que estan unidos, forman un cicloalcan-C3-4-1,1-diilo; R9 y R10 se seleccionan cada uno independientemente de a) H, halo, hidroxi y ciano; (b) alquilo C1-4, cicloalquilo C3-6 y alcoxi C1-4, cada uno sustituido con 0 a 3 sustituyentes opcionales; y (c) fenilo y heteroarilo C1-5, cada uno sustituido con 0 a 3 sustituyentes opcionales; entre otros R11 y R12 se seleccionan cada uno independientemente de (a) H, halo, hidroxi y ciano; y (b) alquilo C1-4, cicloalquilo C3-6 y alcoxi C1-4, cada uno sustituido con 0 a 3 sustituyentes opcionales que se seleccionan independientemente de halo; o, ente otros. Un compuesto seleccionado es 2,2-dimetil-N-(1-metilpiperidin-4-il)-3-((3-metilpiridin-2-il)oxi)propanamida. Dicho compuesto es derivado de piperidinil-3-(ariloxi)propanamida y propanoatos y son moduladores del receptor de somatostatina 4 (SSTR4). Tambien se refiere a su so en el tratamiento de una enfermedad, trastorno o afeccion que se selecciona de enfermedad de Alzheimer, depresion, ansiedad.
PE2020001318A 2018-03-01 2019-02-28 Piperidinil-3-(ariloxi)propanamidas y propanoatos PE20211313A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862637295P 2018-03-01 2018-03-01
PCT/US2019/020086 WO2019169153A1 (en) 2018-03-01 2019-02-28 Piperidinyl-3-(aryloxy)propanamides and propanoates

Publications (1)

Publication Number Publication Date
PE20211313A1 true PE20211313A1 (es) 2021-07-22

Family

ID=65763866

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001318A PE20211313A1 (es) 2018-03-01 2019-02-28 Piperidinil-3-(ariloxi)propanamidas y propanoatos

Country Status (21)

Country Link
US (2) US11045457B2 (es)
EP (1) EP3759094A1 (es)
JP (2) JP7297776B2 (es)
KR (1) KR20200138245A (es)
CN (1) CN112236423B (es)
AR (1) AR114421A1 (es)
AU (1) AU2019228568A1 (es)
BR (1) BR112020017644A2 (es)
CA (1) CA3092450A1 (es)
CL (1) CL2020002257A1 (es)
EA (1) EA202092054A1 (es)
EC (1) ECSP20062464A (es)
IL (1) IL276998B2 (es)
MX (1) MX2020009062A (es)
PE (1) PE20211313A1 (es)
PH (1) PH12020551359A1 (es)
SG (1) SG11202008398XA (es)
TW (1) TWI834637B (es)
UA (1) UA126829C2 (es)
WO (1) WO2019169153A1 (es)
ZA (1) ZA202005438B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI834637B (zh) * 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
GB201901559D0 (en) 2019-02-05 2019-03-27 Syngenta Crop Protection Ag Herbicidal compositions
WO2021143680A1 (zh) 2020-01-16 2021-07-22 浙江海正药业股份有限公司 杂芳基类衍生物及其制备方法和用途
AR121683A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) * 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
WO2021233428A1 (zh) * 2020-05-21 2021-11-25 广州费米子科技有限责任公司 含氮饱和杂环化合物及其制备方法、药物组合物和应用
EP4206175A1 (en) * 2020-08-24 2023-07-05 Hua Medicine (Shanghai) Ltd. Preparation of substituted acrylate compound
CN115477640A (zh) * 2021-05-31 2022-12-16 由理生物医药（上海）有限公司 作为parp7抑制剂的哒嗪酮类化合物
WO2023187677A1 (en) * 2022-03-30 2023-10-05 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
CN1960970A (zh) * 2004-05-28 2007-05-09 田边制药株式会社 作为cb1受体的拮抗剂的吡咯烷衍生物
EP2338881A1 (en) 2005-02-23 2011-06-29 Prexa Pharmaceuticals, Inc. Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications
DK1893603T3 (da) 2005-06-02 2009-11-30 Hoffmann La Roche Piperidin-4-YL-amidderivater og anvendelsen deraf som SST-receptorundertype 5-antagonister
JP4943826B2 (ja) * 2005-11-25 2012-05-30 田辺三菱製薬株式会社 医薬組成物
JP5736098B2 (ja) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド 中枢神経系障害を治療するための医薬組成物
EP2280966A1 (en) 2008-03-14 2011-02-09 Exelixis, Inc. Azabicyclo [3.2.1]octyl derivatives as 11 beta-hsd1 modulators
WO2010059922A1 (en) 2008-11-21 2010-05-27 Ligand Pharmaceuticals Incorporated Pyrrolidine carboxamide compounds
KR20120049940A (ko) 2009-09-04 2012-05-17 노파르티스 아게 키나제 억제제로서의 헤테로아릴 화합물
US9371282B2 (en) 2013-05-17 2016-06-21 Centrexion Therapeutics Corporation Somatostatin receptor subtype 4 (SSTR4) agonists
JPWO2015037716A1 (ja) * 2013-09-12 2017-03-02 住友化学株式会社 含窒素飽和複素環化合物
KR20170082632A (ko) 2014-11-14 2017-07-14 베링거 인겔하임 인터내셔날 게엠베하 소마토스타틴 수용체 아형 4 (sstr4) 작용제로서의 모르폴린 및 1,4-옥사제판 아미드
JP2015037716A (ja) 2014-11-27 2015-02-26 株式会社大一商会 遊技機
EP3317277B1 (en) 2015-07-01 2021-01-20 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TWI834637B (zh) * 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯

Also Published As

Publication number Publication date
UA126829C2 (uk) 2023-02-08
WO2019169153A1 (en) 2019-09-06
CL2020002257A1 (es) 2021-01-29
JP2021515004A (ja) 2021-06-17
TWI834637B (zh) 2024-03-11
US12005054B2 (en) 2024-06-11
IL276998A (en) 2020-10-29
CN112236423A (zh) 2021-01-15
MX2020009062A (es) 2020-10-12
EP3759094A1 (en) 2021-01-06
SG11202008398XA (en) 2020-09-29
TW202000659A (zh) 2020-01-01
BR112020017644A2 (pt) 2021-01-19
IL276998B1 (en) 2023-10-01
US20200061041A1 (en) 2020-02-27
JP7297776B2 (ja) 2023-06-26
EA202092054A1 (ru) 2021-01-22
US11045457B2 (en) 2021-06-29
IL276998B2 (en) 2024-02-01
CN112236423B (zh) 2024-02-06
CA3092450A1 (en) 2019-09-06
ZA202005438B (en) 2023-02-22
ECSP20062464A (es) 2020-12-31
JP2023134444A (ja) 2023-09-27
AR114421A1 (es) 2020-09-02
PH12020551359A1 (en) 2021-08-23
AU2019228568A1 (en) 2020-09-24
KR20200138245A (ko) 2020-12-09
US20230021834A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
PE20211313A1 (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos
AR064355A1 (es) Herbicidas derivados de isoxazol
PE20211050A1 (es) Inhibidores de ptpn11
AR067823A1 (es) Compuestos de amina ciclica
AR105836A1 (es) Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk
AR117923A2 (es) Compuestos 4-amino-6-(4-fenilo sustituido)-picolinatos y 6-amino-2-(4-fenilo sustituido)-pirimidin-4-carboxilatos y composición que los comprende
AR054130A1 (es) Procedimiento para la preparacion de 1-alquil-3-feniluracilos
PE20212247A1 (es) Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos
CO6321244A2 (es) Pirrolopiridinas como inhibidores de cinasa
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
ECSP12012212A (es) Derivados de ariletinilo
AR066946A1 (es) Compuestos heterociclicos antagonistas del receptor de histamina h3, y sus usos terapeuticos
CO6351734A2 (es) Compuestos de amida utiles en terapia
AR105668A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20081851A1 (es) Derivados de espiropiperidina-glicinamida
PE20221083A1 (es) Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
CY1116391T1 (el) Αιθινυλο παραγωγα ως θετικοι αλλοστερικοι ρυθμιστες του mglur5
EA201600403A1 (ru) N-ацилиминогетероциклические соединения
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
PE20160050A1 (es) Inhibidores/ antiandrogenos novedosos de cyp17
PE20191082A1 (es) Inhibidores de la tirosina quinasa de bruton
AR075951A1 (es) Dihidropiridin sulfonamidas y dihidropiridin sulfamidas como inhibidores de mek
CO6321269A2 (es) Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios
AR102731A1 (es) Compuestos espiroisoquinolin-1,4-piperidínicos con actividad multimodal contra el dolor